Investigation of molecular alterations of AKT‐3 in triple‐negative breast cancer

• DOI: 10.1111/his.12313
• Publication Date: 2013-10-19T14:52:42Z
• Authors: Gillian O'Hurley; Etáin Daly; Anthony O'Grady; Robert Cummins; Cecily Quinn; Louise Flanagan; Aisling Pierce; Yue Fan; Miriam A Lynn; Máirín Rafferty; Dara Fitzgerald; Fredrik Pontén; Michael J Duffy; Karin Jirström; Elaine W Kay; William M Gallagher
• Keywords: Triple-negative breast cancer

Aims Triple‐negative breast cancer ( TNBC ) is responsible for a disproportionate number of BC deaths, owing to its intrinsic aggressiveness and lack treatment options, especially targeted therapies. Thus, there an urgent need the development better treatments . Molecular alteration AKT ‐3 was previously reported in oestrogen receptor ER )‐positive has also been suggested play role hormone‐unresponsive The aim this study investigate molecular alterations , perform associated survival analysis, compare these findings with incidence ‐positive Results Our revealed amplification deletions 11% (9/82) 13% (11/82) s, respectively. In contrast, 1% (2/209) s were found have amplifications deletions. A higher prevalence copy gains observed [26% (21/82)] than [9% (19/209)]. together Akt‐3 protein expression negatively recurrence‐free Furthermore, negative association between high observed. Conclusion could represent potentially relevant oncogenic event subset that may, turn, select cells sensitive inhibitors.